Dasatinib (D) inhibits several kinases including SRC and ABL and is currently used as a second line chemotherapeutic agent against imatinib‐resistant chronic myeloid leukemia (Kantarjian et al. 2006; Talpaz et al. 2006). The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.